Volume 1, Number 1, September 2000

The safety and tolerability of candesartan cilexetil in CHF
Erland Erdmann, Michael George, Bernhard Voet, Glyn Belcher, Doris Kolb, Siegfried Hiemstra, Monika Pietrek, Peter Held

The management of congestive heart failure (CHF) continues to represent a major therapeutic challenge. The primary goal of any treatment is the improvement of symptoms with a reduction in CHF related morbidity and a neutral or beneficial effect on mortality. The number of hospitalisations is considered an important measure of morbidity and quality-of-life in these patients.
This pooled safety analysis was performed on adverse event data from five placebo-controlled studies involving a total of 1893 patients, 1287 of whom received candesartan cilexetil and 606 of whom received placebo. These were the only placebo-controlled phase II and III studies of candesartan safety available at the time of the analysis, and investigated the efficacy and safety of candesartan cilexetil in patients with CHF. None was designed as an endpoint trial. A blinded, independent review of all adverse event data was performed to assess all-cause mortality and unexpected deaths, and hospitalisations for acute deterioration of CHF, chronic progression of CHF, other intercurrent events, or accidental injury/attempted suicide. The descriptive analysis included crude and cumulative incidence rates for mortality and cardiac and non-cardiac morbidity using the Kaplan-Meier method and the log-rank test.
The sample population was predominantly (approximately two thirds) male, with a median age of 61 years (range: 20–89 years). The median age for women in the sample population was 66 years (range: 26–86 years). Patients received candesartan cilexetil, 2–32 mg, over a median period of 84 days (range: 1–418 days), or placebo over a median period of 85 days (range: 1–398 days).
The results demonstrated a clinically non-significant trend for all relevant events (deaths and hospitalisations, whether related to CHF or not) to occur less frequently in patients receiving candesartan cilexetil than in patients receiving placebo (deaths – candesartan cilexetil: 1.6%, placebo: 1.8%;   hospitalisations – candesartan cilexetil: 7.2%, placebo: 10.9%). There was a significant treatment difference in CHF hospitalisations (candesartan cilexetil: 3.0% vs. placebo: 5.6%). The time to event analysis revealed that significantly fewer hospitalisations due to CHF occurred in the group receiving candesartan cilexetil than in the group receiving placebo. This treatment difference persisted throughout therapy (log-rank test; p < 0.028).
These results show the safety of candesartan cilexetil, compared with placebo, in the treatment of patients with CHF.

JRAAS 2000;1:31-36.

View full PDF article (open in new window)
Email this article

Right click on this DOI link and copy link to cite this article (What is a DOI link?)